biontech earnings preview. ) is set to give its latest quarterly earnings report on monday 2023-03-27. here'.s what investors need to know before the announcement. analysts estimate that biontech will report an biontech s will hope to hear the comp

biontech signs deal to co-develop oncoc4s cancer drug. germanys biontech se said on monday that it signed a deal with privately held oncoc4 inc to co-develop and commercialize its cancer antibody drug candidate.

biontech signs deal to co-develop oncoc4's cancer drug. germany's biontech se said on monday that it signed a deal with privately held oncoc4 inc to co-develop and commercialize its cancer antibody drug candidate.

bofa securities reiterates buy rating on biontech.

biontech se sponsored adr (bntx) gains as market dips: what you should know. biontech se sponsored adr (bntx) closed at $129.77 in the latest trading session marking a 1.82% move from the prior day. this move outpaced the s&.p 500s

pfizer/biontech seek expanded approval for its updated covid-19 shot as primary series vaccination. ) and) have

pfizer/biontech apply for full approval of updated covid vaccine. pfizer inc and its german partner biontech se said on friday they filed an application to the u.s food and drug administration (fda) for a full approval of their omicron-adapated

biontech becomes oversold (bntx). legendary investor warren buffett advises to be fearful when others are greedy and be greedy when others are fearful. one way we can try to measure the level of fear in a given stock is through a technical

biontech to invest $43 mln in german facility for mrna vaccine building block. biontech will invest 40 million euros ($43 million) in a new facility in germany that will allow it to produce an important building block in mrna-based drugs the ger

biontech seeks to have curevac patent nullified in german court. biontech has filed a motion to have a german patent held by competitor curevac declared invalid in response to a patent lawsuit filed by curevac last year a statement from the germ

biontech to acquire british artificial intelligence startup instadeep. biontech se said on tuesday it will acquire the rest of british artificial intelligence startup instadeep that it does not already own for a total upfront consideration of ab

biontech to acquire instadeep. (rttnews) - biontech se (bntx) and instadeep ltd. have entered into an agreement under which biontech will acquire instadeep a global technology company in the field of artificial intelligence and machine learning.

germanys biontech to acquire british ai startup instadeep. biontech se said on tuesday it would buy the rest of british artificial intelligence startup instadeep that it does not already own for an upfront payment of roughly 362 million euros ($

germanys biontech buys british ai startup instadeep. biontech se has agreed to acquire the british artificial intelligence (ai) startup instadeep for up to 562 million pounds ($682 million) to speed up its biotech research beyond covid shots.

biontech strengthens its artificial intelligence with acquisition of british startup. ) has

biontech says it will start cancer vaccine trials in the uk from september. the company aims to test 10000 personalized mrna therapies including cancer vaccines between september 2023 to the end of the decade.

biontech uk collaborate on personalized mrna cancer immunotherapies.

biontech signs deal with uk for personalised cancer therapies. biontech se has signed a deal with the uk government to enrol up to 10000 patients in clinical trials by the end of 2030 for personalised cancer therapies the german drug maker said.

biontech partners with uk to provide up to 10000 patients with mrna cancer immunotherapies by 2030. (rttnews) - biontech se (bntx) said that it signed a memorandum of understanding with the government of the united kingdom to benefit patients by

biontech: covid market expansion plus car-t therapy improvements.

biontech breaks below 200-day moving average - notable for bntx. in trading on wednesday shares of biontech se (symbol: bntx) crossed below their 200 day moving average of $154.12 changing hands as low as $153.11 per share. biontech se shar